Low-grade gliomas are among the most common primary brain tumors in childhood and can affect patients for life, which is why early diagnosis involving the tumor microenvironment is of significant importance. An international study published in 2025, in which the researchers used imaging mass cytometry to examine over 100 tumor samples at the single-cell level, revealed new therapeutic approaches with the potential combination of blocking the immune checkpoint receptor TIM-3 expressed on myeloid cells with inhibition of the MAPK signaling pathway.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Prurigo nodularis: evidence-based treatment
Targeted therapy options on the rise
- MACE risk, heart failure incidence and all-cause mortality
Metabolic syndrome as a cardiovascular risk factor
- Glaucoma in old age: slowing down progression
IOP lowering is currently the only evidence-based treatment
- Vector-borne infections with skin manifestations
Arboviruses and leishmaniasis in Europe
- Multimorbidity and functional capacity in old age
Clarify individual health status and reduce risks
- Tick season: danger from early summer meningoencephalitis
TBE vaccination recommended for adults and children aged 3 and over
- New WHO guideline, updated stimulation protocols, focus on PGT-A
Fertility and reproductive medicine 2026
- Wound treatment